Gemina Laboratories Ltd. (GLAB.CN) Research

Gemina Laboratories Ltd. is a Canadian biotechnology company dedicated to the research, development, and commercialization of in-vitro diagnostics. The firm invents innovative surface functionalization chemistries for identifying pathogens and biomarkers. Among its current projects, Gemina is advancing the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip specifically designed to detect active COVID-19 infections. The company maintains its headquarters in Vancouver, Canada.

Market snapshot

Symbol
GLAB.CN
Price
$0.06
Day change
0.00%
Market cap
$4.6M
P/E ratio
-1.57x
52-week range
0.05-1.25
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BriaCell Therapeutics Corp. (BCT.TO)
  • Britannia Life Sciences Inc. (BLAB.CN)
  • Rapid Dose Therapeutics Corp. (DOSE.CN)
  • Hemostemix Inc. (HEM.V)
  • Izotropic Corporation (IZO.CN)
  • MediPharm Labs Corp. (LABS.TO)
  • Perimeter Medical Imaging AI, Inc. (PINK.V)
  • Resverlogix Corp. (RVX.TO)

Open Gemina Laboratories Ltd. (GLAB.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.